World Health Organization Raises Concern Over Acute Lack of Obesity Jabs
Under one in 10 patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the WHO as it releases its inaugural advice on the therapies.
With more than one billion individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to this class of drugs.
Per forecasts, more than two billion are projected to be obese by 2030 without intervention.
"The new guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant hurdles to broad access to the jabs that can assist patients in reducing significant body mass, notes the organization.
Skinny Jab Shortage
Despite the present most optimistic scenario, the supply of such drugs would only suffice for around 100 million people – less than 10% of the global need, as stated by the health organization.
The recommendation urges governments and firms to widen availability, by approaches such as patent sharing.
The intellectual property rights on semaglutide – the core component of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Jabs Operate
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so users reduce food intake.
Patients usually see weight reduction after several weeks of beginning the once-weekly jabs.
Studies suggests patients may put most of the weight back on a year later of stopping the medication, because their usual appetite return.
Being above a healthy weight increases your likelihood for experiencing diseases, like diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
